Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 44 Show results per page	View Search Criteria \| Help With Results


1.		TUMORAPA 1: Efficacy of Rapamycin in Secondary Prevention of Skin Cancers in Kidney Transplant Recipients

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care				Active				18 to 80				Other				2003.333 NCT00133887


2.		Immunosuppression in Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care, Treatment				Active				18 and over				Other				SiLVER05 EudraCT Number:, 2005-005362-36, NCT00355862

Last Modified: 9/9/2008 First Published: 9/23/2006


3.		Phase III Randomized Study of Graft-Versus-Host Disease Prophylaxis Comprising Tacrolimus and Methotrexate With or Without Sirolimus in Pediatric Patients With Intermediate-Risk or High-Risk Acute Lymphoblastic Leukemia in Second Complete Remission Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care, Treatment				Active				1 to 21 at first relapse				NCI				COG-ASCT0431 ASCT0431, COG-PBMTC-ONCO51, NCT00382109


4.		Sirolimus-Based Immunosuppression Therapy in OLT for Patients With HCC Exceeding Milan Criteria

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care				Active				18 to 75				Other				ZSH-LCI-FJ-0002 NCT00554125


5.		Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care, Treatment				Active				2 to 55				NCI, NHLBI				385 BMT CTN 0402, U01 HL069294-05, NCT00406393

Last Modified: 9/11/2008 First Published: 11/22/2004


6.		Phase I/II Study of Gefitinib and Sirolimus in Patients With Recurrent or Refractory Stage IIIB or IV Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				NCI, Pharmaceutical / Industry				UCLA-0407057-01 ZENECA-IRUSIRES0281, NCT00098462


7.		Safety Study of Rapamycin Administered Before and During Radiotherapy to Treat Rectum Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				Not specified				Other				04-16 NCT00409994

Last Modified: 7/18/2008 First Published: 3/16/2007


8.		Phase I/II Pilot Study of Sirolimus in Patients with HIV-Related Kaposi's Sarcoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Biomarker/Laboratory analysis, Treatment				Active				18 and over				NCI, Pharmaceutical / Industry				AMC-051 AMC-051, WYETH-0468X-4420, NCT00450320


9.		Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid Malignancies

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Supportive care, Treatment				Active				18 to 70				Other				2005-0682 NCT00473551

First Published: 7/24/2007


10.		Phase I/II Study of Erlotinib Hydrochloride and Sirolimus in Patients With Recurrent Malignant Glioma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Biomarker/Laboratory analysis, Treatment				Active				18 and over				NCI, Pharmaceutical / Industry				UCLA-0604104 OSI3781s, NCT00509431

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute